A new risk assessment tool for GPs is set to revolutionise PCa diagnosis. See here. AndÂ NICE has agreed that abiraterone (Zytiga) is affordable after a lower price was agreed with the makers.Â See here.
We publish several newsletters throughout the year. These provide the latest news and information about the Prospect group and PCa in general.Â The Summer ’23 newsletter is downloadable via this link (click link or right click and save as…). This issue of the newsletter has news about our summer meetings, the botanic garden tour and the docks walk. There is also an article on psychological approaches in recovery. David Casley, Prospect Publicity 07860 369064;Â EmailÂ firstname.lastname@example.org
Patients might be offered a more accurate prediction of their PCa risk with a novel method developed by Cambridge University researchers. See here